Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • yl01
    Member
    • Aug 2012
    • 25

    #1

    Gene panel exome data

    Hello,

    I have got exome sequencing data from 24 samples. It was done on a MiSeq sequencer. The data are not whole exome data, instead it is gene panel of about 200 genes. I have processed the whole data using the usual whole exome pipeline BWA+GATK, of course with the corresponding bed file. It turned out that the PCR duplication rate in majority of the samples is very high, 70% to 90%. This also caused the mean coverage to be very low, about 4. I am wondering if this is normal in gene panel data. And is it OK in gene panel sequencings to not remove PCR duplicates. Any other points regarding the processing of gene panel exome data is much appreciated.
  • nexgengirl
    Member
    • Apr 2010
    • 31

    #2
    How was the DNA prepared? Was it hybridization or pcr based design? If it was PCR-based you would expect high PCR duplication rate but if it was hybridization based then yes this is high.

    Comment

    • yl01
      Member
      • Aug 2012
      • 25

      #3
      Thank you nexgengirl! I know it was using Agilent HaloPlex technology. So I think it is hybridization based. Right?

      Comment

      • Bukowski
        Senior Member
        • Jan 2010
        • 388

        #4
        Originally posted by yl01 View Post
        Thank you nexgengirl! I know it was using Agilent HaloPlex technology. So I think it is hybridization based. Right?
        Sort of - there's also an amplification step. Read the protocol. You can't deduplicate Halo data, it's not like working with SureSelect. Effectively you get mini-amplicon regions that match up with the restriction digest sites used.

        Comment

        • nexgengirl
          Member
          • Apr 2010
          • 31

          #5
          I have not personally used the Haloplex platform before. I've analyzed a lot of exome data but not Haloplex.

          From briefly looking at the information on the Agilent site it seems that first the DNA is fragmented with restriction enzymes which will be exact cuts (as opposed to "random" shearing in typical exome experiments), second the probes are hybridized (the way its described this also seems very specific since its to the ends of restriction fragments), third the targets are purified and ligated, fourth there is a PCR step, and then fifth sequencing.

          From my interpretation of this setup I would think it would be okay to retain the PCR duplicates (since there's PCR in the 4th step to enrich for your targets) but I would hope someone else who has used the Haloplex technology could comment on this as well.

          Comment

          • nexgengirl
            Member
            • Apr 2010
            • 31

            #6
            See Bukowski answer. It came up as I was entering the previous post.

            Comment

            • yl01
              Member
              • Aug 2012
              • 25

              #7
              Thank you nexgengirl and Bukowski!

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                by SEQadmin2



                CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                Despite this, “CRISPR helped turn genome editing from a specialized technique into
                ...
                07-31-2026, 11:01 AM
              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                07-20-2026, 11:48 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Yesterday, 12:22 PM
              0 responses
              12 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 08-11-2026, 10:35 AM
              0 responses
              14 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 08-06-2026, 07:41 AM
              0 responses
              31 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 08-03-2026, 10:13 AM
              0 responses
              49 views
              0 reactions
              Last Post SEQadmin2  
              Working...